

Rui-Chao Chai

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8833338/publications.pdf>

Version: 2024-02-01

37
papers

1,861
citations

361296
20
h-index

414303
32
g-index

40
all docs

40
docs citations

40
times ranked

1628
citing authors

#	ARTICLE	IF	CITATIONS
1	Chinese Glioma Genome Atlas (CGGA): A Comprehensive Resource with Functional Genomic Data from Chinese Glioma Patients. <i>Genomics, Proteomics and Bioinformatics</i> , 2021, 19, 1-12.	3.0	439
2	m6A RNA methylation regulators contribute to malignant progression and have clinical prognostic impact in gliomas. <i>Aging</i> , 2019, 11, 1204-1225.	1.4	209
3	Clinical practice guidelines for the management of adult diffuse gliomas. <i>Cancer Letters</i> , 2021, 499, 60-72.	3.2	194
4	YTHDF2 facilitates UBXN1 mRNA decay by recognizing METTL3-mediated m6A modification to activate NF- κ B and promote the malignant progression of glioma. <i>Journal of Hematology and Oncology</i> , 2021, 14, 109.	6.9	92
5	METTL3 enhances the stability of MALAT1 with the assistance of HuR via m6A modification and activates NF- κ B to promote the malignant progression of IDH-wildtype glioma. <i>Cancer Letters</i> , 2021, 511, 36-46.	3.2	86
6	Identification of an energy metabolism-related signature associated with clinical prognosis in diffuse glioma. <i>Aging</i> , 2018, 10, 3185-3209.	1.4	72
7	ADAMTSL4, a Secreted Glycoprotein, Is a Novel Immune-Related Biomarker for Primary Glioblastoma Multiforme. <i>Disease Markers</i> , 2019, 2019, 1-12.	0.6	66
8	Systematically characterize the clinical and biological significances of 1p19q genes in 1p/19q non-codeletion glioma. <i>Carcinogenesis</i> , 2019, 40, 1229-1239.	1.3	60
9	Prognostic power of a lipid metabolism gene panel for diffuse gliomas. <i>Journal of Cellular and Molecular Medicine</i> , 2019, 23, 7741-7748.	1.6	59
10	The molecular characteristics of spinal cord gliomas with or without H3 K27M mutation. <i>Acta Neuropathologica Communications</i> , 2020, 8, 40.	2.4	51
11	Classification of diffuse lower-grade glioma based on immunological profiling. <i>Molecular Oncology</i> , 2020, 14, 2081-2095.	2.1	48
12	Combinations of four or more CpGs methylation present equivalent predictive value for MGMT expression and temozolomide therapeutic prognosis in gliomas. <i>CNS Neuroscience and Therapeutics</i> , 2019, 25, 314-322.	1.9	42
13	Molecular subtyping reveals immune alterations in IDH-wildtype lower-grade diffuse glioma. <i>Journal of Pathology</i> , 2020, 251, 272-283.	2.1	42
14	A novel analytical model of MGMT methylation pyrosequencing offers improved predictive performance in patients with gliomas. <i>Modern Pathology</i> , 2019, 32, 4-15.	2.9	41
15	Amino acid metabolism-related gene expression-based risk signature can better predict overall survival for glioma. <i>Cancer Science</i> , 2019, 110, 321-333.	1.7	39
16	Molecular classification of IDH-mutant glioblastomas based on gene expression profiles. <i>Carcinogenesis</i> , 2019, 40, 853-860.	1.3	37
17	A novel gene signature based on five glioblastoma stem-like cell relevant genes predicts the survival of primary glioblastoma. <i>Journal of Cancer Research and Clinical Oncology</i> , 2018, 144, 439-447.	1.2	36
18	Expression profile analysis of antisense long non-coding RNA identifies WDFY3-AS2 as a prognostic biomarker in diffuse glioma. <i>Cancer Cell International</i> , 2018, 18, 107.	1.8	33

#	ARTICLE	IF	CITATIONS
19	Predictive value of MGMT promoter methylation on the survival of TMZ treated <i>IDH</i>-mutant glioblastoma. <i>Cancer Biology and Medicine</i> , 2021, 18, 271-282.	1.4	31
20	Systematically profiling the expression of eIF3 subunits in glioma reveals the expression of eIF3i has prognostic value in IDH-mutant lower grade glioma. <i>Cancer Cell International</i> , 2019, 19, 155.	1.8	27
21	A Novel DNA Methylation-Based Signature Can Predict the Responses of MGMT Promoter Unmethylated Glioblastomas to Temozolomide. <i>Frontiers in Genetics</i> , 2019, 10, 910.	1.1	22
22	RNA processing genes characterize RNA splicing and further stratify lower-grade glioma. <i>JCI Insight</i> , 2019, 5, .	2.3	20
23	Clinicopathological characteristics and survival of spinal cord astrocytomas. <i>Cancer Medicine</i> , 2020, 9, 6996-7006.	1.3	18
24	Spinal Cord Diffuse Midline Gliomas With H3 K27m-Mutant: Clinicopathological Features and Prognosis. <i>Neurosurgery</i> , 2021, 89, 300-307.	0.6	18
25	Gene Expression Profiling Stratifies IDH-Wildtype Glioblastoma With Distinct Prognoses. <i>Frontiers in Oncology</i> , 2019, 9, 1433.	1.3	16
26	ABCC8 mRNA expression is an independent prognostic factor for glioma and can predict chemosensitivity. <i>Scientific Reports</i> , 2020, 10, 12682.	1.6	14
27	Transcriptional Characteristics of IDH-Wild Type Glioma Subgroups Highlight the Biological Processes Underlying Heterogeneity of IDH-Wild Type WHO Grade IV Gliomas. <i>Frontiers in Cell and Developmental Biology</i> , 2020, 8, 580464.	1.8	8
28	A comprehensive model including preoperative peripheral blood inflammatory markers for prediction of the prognosis of diffuse spinal cord astrocytoma following surgery. <i>European Spine Journal</i> , 2021, 30, 2857-2866.	1.0	7
29	Recurrent PTPRZ1<math>\hat{=}</math>MET fusion and a high occurrence rate of MET exon 14 skipping in brain metastases. <i>Cancer Science</i> , 2022, 113, 796-801.	1.7	7
30	Molecular Characterization and Clinical Relevance of ANXA1 in Gliomas via 1,018 Chinese Cohort Patients. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 777182.	1.8	6
31	Characterization and prognostic significance of alternative splicing events in lower<math>\hat{=}</math>grade diffuse gliomas. <i>Journal of Cellular and Molecular Medicine</i> , 2020, 24, 13171-13180.	1.6	4
32	Hypoxia induced LBH overexpression accelerates malignant progression in glioma. <i>EBioMedicine</i> , 2019, 49, 4-5.	2.7	1
33	A potentially effective drug for patients with recurrent glioma: sermorelin. <i>Annals of Translational Medicine</i> , 2021, 9, 406-406.	0.7	1
34	PATH-60. BIOINFORMATIC PROFILING IDENTIFIES THE SECRETED GLYCOPROTEIN ADAMTSL4 TO BE A POTENTIAL NOVEL IMMUNE-RELATED BIOMARKER FOR PRIMARY GLIOBLASTOMA. <i>Neuro-Oncology</i> , 2018, 20, vi171-vi172.	0.6	0
35	PATH-61. A NOVEL ANALYSIS MODEL OF MGMT METHYLATION PYROSEQUENCING OFFERS AN OPTIMAL PREDICTIVE PERFORMANCE IN GLIOMAS. <i>Neuro-Oncology</i> , 2018, 20, vi172-vi172.	0.6	0
36	1p19q Gene Transcription Profiles Closely Correlated to Malignancy and Prognosis of 1p/19q Non-Codeletion Gliomas. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0

#	ARTICLE	IF	CITATIONS
37	Systematic Profiling of Alternative Splicing in Lower-Grade Diffuse Gliomas. SSRN Electronic Journal, 0, , .	0.4	0